

FIG. 1




FIG. 2




FIG. 3




FIG. 4A




FIG. 4B





FIG. 5






FIG. 7




FIG. 8




FIG. 9




FIG. 10A




FIG. 10B




FIG. 11A




FIG. 11B




FIG. 11C




FIG. 12

FcRH5/CD3 GO39775 (data cut: Aug, 2020)





FIG. 13






FIG. 14A




FIG. 14C

IFN- γ induction in plasma




FIG. 15A IL-6 kinetics in plasma in C1




FIG. 15B




FIG. 16A

Change in CD8+ tumor-infiltrating T-cell levels in responders and non-responders in C1




FIG. 16B

Pre-treatment vs on-treatment level of CD8+ tumor-infiltrating
T cells in a patient with sCR by IHC




FIG. 17

CRS by cycle and highest grade




FIG. 18




FIG. 19




FIG. 20




FIG. 21




FIG. 22B




FIG. 22C




FIG. 23A





FIG. 23B






FIG. 24




FIG. 25




FIG. 26




FIG. 27B






FIG. 27A






FIG. 29




FIG. 30A




FIG. 30B




FIG. 31








FIG. 32










FIG. 35







FIG. 36







*190001, 200003, 230001, 350005, 350031,
220002, 300006 removed due to inconsistent dosing




FIG. 39




FIG. 40A




FIG. 40B




FIG. 41A




FIG. 41B




FIG. 42




FIG. 43

